Natasa Rajicic

Natasa Rajicic has enjoyed being a biostatistician for over 20 years. As Senior Director of Strategic Consulting at Cytel, she helps clients address difficult questions around study designs and overall drug development. Prior to joining Cytel, Rajicic worked as a biostatistician at Pfizer, New York for 11 years, where she was Director, Statistics Group Lead for endocrine care statistics. Earlier in her career, Rajicic spent 5 years at the Center for Biostatistics in AIDS Research at Harvard School of Public Health in Boston. She also worked as a consulting biostatistician at the Massachusetts General Hospital Biostatistics Unit where she did her doctoral research in survival analysis of longitudinal microarray data. Natasa is an author on over 30 scientific publications. Rajicic received a B.A. in Mathematics and a MS in Statistics from West Virginia University, and a doctorate degree in Biostatistics from Harvard School of Public Health.

Recent Posts

Novel immunotherapies lean on old methods (or how to teach your dragon old tricks)

Posted by Natasa Rajicic

Sep 17, 2018 5:25:00 AM

 

Immunotherapy has brought us many promises, most notably, of a future where humans are able to harness their body’s own ability to protect them from illness. Immuno-oncology (IO) may be the ultimate frontier of that future reality, with a promise of being able to help our bodies deflect or cure us of any malignancies. Today, these therapies include cell therapies, cancer vaccine, and...

Read More

Topics: Oncology, immunotherapy, biostatistics


The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.  Sign up for updates direct to your inbox. You can unsubscribe at any time.

 

Posts by Topic

see all

Recent Posts